Rana Al-Hallaq, PHD is Executive Director, WWBD and Partner at Pfizer Ventures. Rana is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Arkuda Therapeutics, Autifony Therapeutics, Biograph55, Blade Therapeutics, Jnana Therapeutics, Magnolia NeuroSciences, Mitokinin, Montis BioSciences, ReCode Therapeutics, RefleXion Medical, Triplet Therapeutics, and Vivet Therapeutics. Her prior investment responsibilities include Cortexyme and VectivBio. She is also responsible for managing investments in the Dementia Discovery Fund and the Health Enterprise Partners Fund.

Prior to her current role, Rana was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies investigating novel treatments for Major Depressive Disorder and schizophrenia, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas. She began her training as a research fellow at the National Institutes of Health.

Rana received her BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.